Europe Real Time Polymerase Chain Reaction (qPCR) Market Analysis By Instrument (7500, Quantstudio Dx, ViiA 7 Dx, StepOne/StepOne Plus, LightCycler 2.0, Cobas 4800, LightCycler 480, CFX96, SmartCycler, Rotor-Gene Q, MasterCycler), And Segment Forecasts to 2022
Europe Real Time Polymerase Chain Reaction (qPCR) market is expected to reach over USD 395.8 million by 2022, according to a new report by Grand View Research Inc. Technological advancements on the grounds of accuracy, portability, and cost-effectiveness are expected to serve this market as high-impact rendering drivers over the forecast period. For instance, Applied Biosystems has QuantStudio Dx series for rapid and affordable diagnosis of molecular abnormalities at early stage of diseases development.
Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use.
Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders.
Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK’s MEGA-A3 cancer immunotherapy.
Emerging opportunities for both companies for development of products pertaining to early detection of diseases such as cancer and infectious diseases are estimated to enhance such collaborative activities over the forecast period.
Further key findings from the study suggest:
Thermo Fisher/ABI dominated the market with a revenue share of over 38% in 2014 owing to high installed base of instruments such as StepOne, 7500, ViiA 7, and QuantStudio from ABI
Bio-Rad qPCR instruments market is the second largest in terms of revenue share over USD 7.0 million in 2014. Presence of licensing agreement with companies such as Mobidiag in Europe for the distribution Bio-Rad qPCR instruments, availability of user-friendly software and good technical support are some factors attributing for its high market coverage.
Thermo Fischer Scientific, Roche, Bio-Rad, and Qiagen accounted for over 84% of market share in 2014. Product development and distribution agreements are the key strategies adopted by the company for its growth. Whereas, the four countries namely UK, Germany, Spain and France covered around 56% of the total European market for qPCR used as IVD platform in 2014.
Germany dominated the European market with revenue of around USD 9.5 million in 2014. It is estimated to be one of the major countries for use of In-Vitro Diagnostics (IVD) platform in Europe.
The UK is expected to witness significant growth with a CAGR of around 13% over the forecast period owing to rising prevalence of target diseases and introduction of new automated technologies.
Countries such as France and Spain are experiencing economic growth over the past few years; these countries are expected to offer immense potential for Europe real time PCR industry mainly due to growing economy and high unmet needs
Market participants are constantly engaged in the introduction of technological advancements. The real time PCR instruments market involves extensive technological advancements to match user requirements.
Increasing amount of R&D expenditure by the major players and development of novel assay kits are expected to provide potential growth platform for adoption of qPCR instruments for diagnostic use.
Growing prevalence of cancer and other chronic diseases is anticipated to be the key driver for the industry growth. Moreover, growing geriatric population base in EU-28 countries is expected to increase age-related conditions such as diabetes and cardiovascular disorders.
Furthermore, major pharmaceutical companies are entering into collaborations with diagnostic instrument development companies through mergers and acquisitions or co-product development activities. For instance, in 2011, Life Technologies signed an agreement with GSK Biologicals to develop a companion diagnostic test. Life Technology will develop a qPCR based diagnostic assay for GSK’s MEGA-A3 cancer immunotherapy.
Emerging opportunities for both companies for development of products pertaining to early detection of diseases such as cancer and infectious diseases are estimated to enhance such collaborative activities over the forecast period.
Further key findings from the study suggest:
Thermo Fisher/ABI dominated the market with a revenue share of over 38% in 2014 owing to high installed base of instruments such as StepOne, 7500, ViiA 7, and QuantStudio from ABI
Bio-Rad qPCR instruments market is the second largest in terms of revenue share over USD 7.0 million in 2014. Presence of licensing agreement with companies such as Mobidiag in Europe for the distribution Bio-Rad qPCR instruments, availability of user-friendly software and good technical support are some factors attributing for its high market coverage.
Thermo Fischer Scientific, Roche, Bio-Rad, and Qiagen accounted for over 84% of market share in 2014. Product development and distribution agreements are the key strategies adopted by the company for its growth. Whereas, the four countries namely UK, Germany, Spain and France covered around 56% of the total European market for qPCR used as IVD platform in 2014.
Germany dominated the European market with revenue of around USD 9.5 million in 2014. It is estimated to be one of the major countries for use of In-Vitro Diagnostics (IVD) platform in Europe.
The UK is expected to witness significant growth with a CAGR of around 13% over the forecast period owing to rising prevalence of target diseases and introduction of new automated technologies.
Countries such as France and Spain are experiencing economic growth over the past few years; these countries are expected to offer immense potential for Europe real time PCR industry mainly due to growing economy and high unmet needs
Market participants are constantly engaged in the introduction of technological advancements. The real time PCR instruments market involves extensive technological advancements to match user requirements.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
1.4 Known, Unknown variables & target segment
1.5 Known variable derivation: Market size & dynamics
1.6 Unknown variable derivation: Market size & dynamics
1.7 Company Market Share Analysis : Methodology
1.8 Country wise market calculation
1.8.1 Country wise market: Base estimates
1.8.2 Global market: CAGR calculation
1.9 Region based segment share calculation
1.10 Limitations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Real time polymerase chain reaction (qPCR) market
CHAPTER 3 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) INDUSTRY OUTLOOK
3.1 Europe Real Time Polymerase Chain Reaction (qPCR) market size and growth prospects, 2012 - 2022
3.2 Europe Real Time Polymerase Chain Reaction (qPCR): Market dynamics
3.2.1 Market driver analysis
3.2.1.1 Growing geriatric population base
3.2.1.2 Introduction of technological advancements
3.2.1.3 Increasing prevalence of cancer and other chronic diseases
3.2.1.4 Increasing collaborations between pharmaceutical companies and medical device companies
3.2.2 Market Restraint Analysis
3.2.2.1 Presence of ambiguous regulatory framework
3.2.2.2 High prices of diagnostics tests and instruments
3.3 Europe real time polymerase chain reaction (qPCR) market industry trend analysis
3.4 Europe real time polymerase chain reaction (qPCR) market: PESTEL analysis
3.5 Industry analysis Porter’s
3.6 Europe real time polymerase chain reaction (qPCR) company market share analysis, 2014
CHAPTER 4 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) INSTRUMENT OUTLOOK
4.1 7500 FAST DX Real-Time PCR System, with laptop computer
4.1.1 7500 FAST DX Real-Time PCR System, with laptop computer market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.2 7500 FAST DX Real-Time PCR System, with PC tower
4.2.1 7500 FAST DX Real-Time PCR System, with PC tower market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.3 QuantStudio DX Real-Time PCR System, 384-well
4.3.1 QuantStudio DX Real-Time PCR System, 384-well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.4 QuantStudio DX Real-Time PCR System, 96-well Fast
4.4.1 QuantStudio DX Real-Time PCR System, 96-well Fast market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.5 QuantStudio DX Real-Time PCR System, 96-well
4.6.1 QuantStudio DX Real-Time PCR System, 96-well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.6 QuantStudio DX Real-Time PCR System, array card
4.6.1 QuantStudio DX Real-Time PCR System, array card market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.7 ViiA 7 Dx 96 Well Real-Time PCR With Laptop
4.7.1 ViiA 7 Dx 96 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.8 ViiA 7 Dx 384 Well Real-Time PCR With Laptop
4.8.1 ViiA 7 Dx 384 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.9 ViiA 7 Dx Fast 96 Well Real-Time PCR With Laptop
4.9.1 ViiA 7 Dx Fast 96 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.10 ViiA 7 Dx 96 Well Real-Time PCR With Desktop
4.10.1 ViiA 7 Dx 96 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.11 ViiA 7 Dx 384 Well Real-Time PCR With Desktop
4.11.1 ViiA 7 Dx 384 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.12 ViiA 7 Dx Array Card Real-Time PCR With Desktop
4.12.1 ViiA 7 Dx Array Card Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.13 ViiA 7 Dx Fast 96 Well Real-Time PCR With Desktop
4.13.1 ViiA 7 Dx Fast 96 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.14 ABI StepOne system
4.14.1 ABI StepOne system market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.15 ABI StepOnePlus system
4.15.1 ABI StepOnePlus system market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.16 LightCycler 2.0
4.16.1 LightCycler 2.0 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.17 Cobas 4800
4.17.1 Cobas 4800 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.18 LightCycler
4.18.1 LightCycler 480 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.19 CFX96
4.19.1 CFX96 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.20 CFX96 Deep Well
4.20.1 CFX96 Deep Well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.21 SmartCycler
4.21.1 SmartCycler market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.22 DTprime 4M1 Real Time PCR
4.22.1 DTprime 4M1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.23 DTprime 5M1 Real Time PCR
4.23.1 DTprime 5M1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.24 DTlite 4S1 Real Time PCR
4.24.1 DTlite 4S1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.25 DTlite 5S1 Real Time PCR
4.25.1 DTlite 5S1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.26 Rotor-Gene Q 5plex HRM System
4.26.1 Rotor-Gene Q 5plex HRM System market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.27 MasterCycler
4.27.1 MasterCycler market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
CHAPTER 5 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) REGIONAL OUTLOOK
5.1 Europe Real Time Polymerase Chain Reaction (qPCR) Market Share By country, 2014 & 2022
5.2 UK
5.2.1 UK Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.3 Germany
5.3.1 Germany Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.4 Spain
5.4.1 Spain Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.5 France
5.5.1 France Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
1.4 Known, Unknown variables & target segment
1.5 Known variable derivation: Market size & dynamics
1.6 Unknown variable derivation: Market size & dynamics
1.7 Company Market Share Analysis : Methodology
1.8 Country wise market calculation
1.8.1 Country wise market: Base estimates
1.8.2 Global market: CAGR calculation
1.9 Region based segment share calculation
1.10 Limitations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Real time polymerase chain reaction (qPCR) market
CHAPTER 3 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) INDUSTRY OUTLOOK
3.1 Europe Real Time Polymerase Chain Reaction (qPCR) market size and growth prospects, 2012 - 2022
3.2 Europe Real Time Polymerase Chain Reaction (qPCR): Market dynamics
3.2.1 Market driver analysis
3.2.1.1 Growing geriatric population base
3.2.1.2 Introduction of technological advancements
3.2.1.3 Increasing prevalence of cancer and other chronic diseases
3.2.1.4 Increasing collaborations between pharmaceutical companies and medical device companies
3.2.2 Market Restraint Analysis
3.2.2.1 Presence of ambiguous regulatory framework
3.2.2.2 High prices of diagnostics tests and instruments
3.3 Europe real time polymerase chain reaction (qPCR) market industry trend analysis
3.4 Europe real time polymerase chain reaction (qPCR) market: PESTEL analysis
3.5 Industry analysis Porter’s
3.6 Europe real time polymerase chain reaction (qPCR) company market share analysis, 2014
CHAPTER 4 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) INSTRUMENT OUTLOOK
4.1 7500 FAST DX Real-Time PCR System, with laptop computer
4.1.1 7500 FAST DX Real-Time PCR System, with laptop computer market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.2 7500 FAST DX Real-Time PCR System, with PC tower
4.2.1 7500 FAST DX Real-Time PCR System, with PC tower market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.3 QuantStudio DX Real-Time PCR System, 384-well
4.3.1 QuantStudio DX Real-Time PCR System, 384-well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.4 QuantStudio DX Real-Time PCR System, 96-well Fast
4.4.1 QuantStudio DX Real-Time PCR System, 96-well Fast market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.5 QuantStudio DX Real-Time PCR System, 96-well
4.6.1 QuantStudio DX Real-Time PCR System, 96-well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.6 QuantStudio DX Real-Time PCR System, array card
4.6.1 QuantStudio DX Real-Time PCR System, array card market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.7 ViiA 7 Dx 96 Well Real-Time PCR With Laptop
4.7.1 ViiA 7 Dx 96 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.8 ViiA 7 Dx 384 Well Real-Time PCR With Laptop
4.8.1 ViiA 7 Dx 384 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.9 ViiA 7 Dx Fast 96 Well Real-Time PCR With Laptop
4.9.1 ViiA 7 Dx Fast 96 Well Real-Time PCR With Laptop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.10 ViiA 7 Dx 96 Well Real-Time PCR With Desktop
4.10.1 ViiA 7 Dx 96 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.11 ViiA 7 Dx 384 Well Real-Time PCR With Desktop
4.11.1 ViiA 7 Dx 384 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.12 ViiA 7 Dx Array Card Real-Time PCR With Desktop
4.12.1 ViiA 7 Dx Array Card Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.13 ViiA 7 Dx Fast 96 Well Real-Time PCR With Desktop
4.13.1 ViiA 7 Dx Fast 96 Well Real-Time PCR With Desktop market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.14 ABI StepOne system
4.14.1 ABI StepOne system market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.15 ABI StepOnePlus system
4.15.1 ABI StepOnePlus system market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.16 LightCycler 2.0
4.16.1 LightCycler 2.0 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.17 Cobas 4800
4.17.1 Cobas 4800 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.18 LightCycler
4.18.1 LightCycler 480 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.19 CFX96
4.19.1 CFX96 market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.20 CFX96 Deep Well
4.20.1 CFX96 Deep Well market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.21 SmartCycler
4.21.1 SmartCycler market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.22 DTprime 4M1 Real Time PCR
4.22.1 DTprime 4M1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.23 DTprime 5M1 Real Time PCR
4.23.1 DTprime 5M1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.24 DTlite 4S1 Real Time PCR
4.24.1 DTlite 4S1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.25 DTlite 5S1 Real Time PCR
4.25.1 DTlite 5S1 Real Time PCR market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.26 Rotor-Gene Q 5plex HRM System
4.26.1 Rotor-Gene Q 5plex HRM System market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
4.27 MasterCycler
4.27.1 MasterCycler market estimates and forecasts, 2012 - 2022 revenue (USD Million), volume (units)
CHAPTER 5 EUROPE REAL TIME POLYMERASE CHAIN REACTION (QPCR) REGIONAL OUTLOOK
5.1 Europe Real Time Polymerase Chain Reaction (qPCR) Market Share By country, 2014 & 2022
5.2 UK
5.2.1 UK Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.3 Germany
5.3.1 Germany Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.4 Spain
5.4.1 Spain Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
5.5 France
5.5.1 France Real Time Polymerase Chain Reaction (qPCR) Market Estimates and Forecasts, by Instrument, 2012 - 2022, Revenue (USD Million), Volume (units)
